Shire completes tender offer for NPS Pharma shares
Shire has successfully completed a tender offer for all outstanding shares of NPS Pharmaceuticals.
Chief executive at Shire, Flemming Ornskov said: "We are delighted to have completed the acquisition of NPS Pharma, and look forward to working with their talented employees to transform the lives of patients with rare diseases and specialty conditions.
“Shire's global strength and expertise in both rare diseases and GI medicines, coupled with NPS Pharma's rare disease capabilities, and our shared deep commitment to serving the needs of patients, make this an excellent strategic fit.
“Together, we aim to provide more patients and their families around the world with much needed medicines and enhanced support services."
According to Shire, this offer expired on 20 February 2015 and was not extended. As of this expiration date the number of NPS Pharma’s outstanding shares totalled 88,869,118 and they had all been validly tendered.
The company added that all common shares of NPS Pharma that were not accepted for payment in the tender offer were converted into the right to receive $46 per share in cash without interest and less any applicable withholding taxes. This quotes the price to be paid for shares accepted for payment in the tender offer.